Flamigel® for the prevention¹ and treatment² of Radiotherapy-induced Skin Reactions

95% of all cancer patients treated with radiotherapy¹ experience skin reactions. Flamigel® is clinically proven to:

› Reduce moist desquamation¹
› Restore the moisture balance of the skin
› Soothe pain²
› Reduce inflammation

Flamigel® reduces the incidence of moist desquamation by 80% when used from the start of radiotherapy.¹

Flamigel® prevents the onset of moist desquamation in 93% of patients when used from the start of radiotherapy.¹

The preventive or the curative use of a colloidal hydroactive gel Flamigel® during radiotherapy, in comparison with the use of dexpanthenol significantly reduces the risk of radiation-induced moist desquamation.

Always read the label. Follow the directions for use. If symptoms persist consult your health professional.

For further information or to receive a sample, call 1300 9 ARROW (27769)